ALS Research
Amyotrophic Lateral Sclerosis
Key Facts
About GliaPharm
GliaPharm is a private, preclinical-stage biotech leveraging decades of glial cell research to develop neuroprotective therapies. The company has established the GliaX technology platform to discover and develop small molecules targeting glial cells, with an initial focus on Alzheimer's disease, epilepsy, and ALS. Backed by a strong scientific foundation from co-founder Prof. Pierre Magistretti and led by an experienced executive team, the company has secured non-dilutive funding, including a $4.2M investment from the Alzheimer's Drug Discovery Foundation (ADDF) in 2023. GliaPharm represents a novel approach in neurology by targeting non-neuronal cells, aiming to address high-unmet-need conditions with limited treatment options.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| ALS Program | Biogen | Multiple Phases |
| Reldesemtiv | Cytokinetics | Phase 3 |
| Cell Therapy for ALS | INCELL | Unknown |
| ALS Disease Model Service | NeuroProof | Pre-clinical |